Indaptus Therapeutics, Inc. has filed an 8-K report detailing significant changes in its corporate structure and leadership. The report, dated March 24, 2026, outlines a Securities Purchase Agreement entered into by the company on December 22, 2025, with David E. Lazar, who purchased 300,000 shares of Series AA Convertible Preferred Stock and 700,000 shares of Series AAA Convertible Preferred Stock. This transaction allows for the conversion of these shares into a total of 111 million shares of common stock, significantly impacting the company's equity structure.

On March 23, 2026, Lazar sold his interests in the preferred stock to several purchasers for a total of $11.2 million. This transaction is expected to dilute existing shareholders' equity, as the conversion of preferred shares into common stock will increase the total number of shares outstanding.

Additionally, the report notes the resignation of several key directors, including Jeffrey A. Meckler and Roger J. Pomerantz, as well as David Lazar stepping down as co-CEO while remaining on the board. Junyi Dai has been appointed as the new Chairman and CEO, effective immediately. These leadership changes may lead to a shift in the company's strategic direction, which could affect investor confidence and stock performance.

The filing also includes details about the company's financial statements and exhibits, indicating a commitment to transparency during this transitional period. The overall impact of these changes on the company's stock price remains to be seen, but the dilution of shares and leadership changes could lead to a cautious outlook from investors.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.